Bioventus (NYSE:BVS) Reaches New 1-Year High – Still a Buy?

Bioventus Inc. (NYSE:BVS)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $13.15 and last traded at $13.09, with a volume of 20910 shares trading hands. The stock had previously closed at $12.97.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BVS shares. Canaccord Genuity Group increased their price target on Bioventus from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Craig Hallum increased their target price on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, September 27th.

Bioventus Trading Up 0.5 %

The stock’s 50-day moving average price is $10.95 and its 200 day moving average price is $7.76. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.33 and a quick ratio of 0.96. The firm has a market capitalization of $1.06 billion, a PE ratio of -38.14 and a beta of 0.90.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.12. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. The business had revenue of $151.22 million during the quarter, compared to analyst estimates of $137.70 million. During the same period in the previous year, the company posted $0.14 EPS. On average, sell-side analysts expect that Bioventus Inc. will post 0.4 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bioventus news, Director John A. Bartholdson purchased 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The stock was acquired at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the acquisition, the director now owns 6,939,357 shares in the company, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director John A. Bartholdson acquired 80,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the purchase, the director now directly owns 6,913,857 shares of the company’s stock, valued at $59,113,477.35. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director John A. Bartholdson bought 25,500 shares of the business’s stock in a transaction on Monday, August 19th. The stock was bought at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the purchase, the director now directly owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 32.90% of the stock is owned by company insiders.

Institutional Trading of Bioventus

A number of institutional investors have recently modified their holdings of BVS. Quadrature Capital Ltd purchased a new stake in Bioventus during the fourth quarter valued at approximately $85,000. LSV Asset Management acquired a new stake in shares of Bioventus in the 1st quarter worth $1,170,000. SG Americas Securities LLC purchased a new position in Bioventus during the 1st quarter worth $66,000. Acadian Asset Management LLC acquired a new position in Bioventus during the 1st quarter valued at about $28,000. Finally, Hillsdale Investment Management Inc. raised its stake in Bioventus by 26.1% in the first quarter. Hillsdale Investment Management Inc. now owns 34,742 shares of the company’s stock valued at $181,000 after buying an additional 7,200 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.